Katy Lísias Gondim Dias de Albuquerque

Katy Lísias Gondim Dias de Albuquerque

Auto-generated profile, based on publicly available information

Katy Lísias Gondim Dias de Albuquerque

Federal University of Paraíba João Pessoa Paraíba Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Trends in Psychiatry and Psychotherapy
Verified
Journal Article
Open access
PDF file
EJEstácio Amaro da Silva Junior
Estácio Amaro da Silva Junior
WMWandersonia Moreira Brito Medeiros
Wandersonia Moreira Brito Medeiros
JSJoão Paulo Mendes dos Santos
João Paulo Mendes dos Santos
JSJoão Marçal Medeiros de Sousa
João Marçal Medeiros de Sousa
FCFilipe Barbosa da Costa
Filipe Barbosa da Costa
KAKaty Lísias Gondim Dias de Albuquerque
Katy Lísias Gondim Dias de Albuquerque
Trends Psychiatry Psychother, vol.0, nAheadOfPrint, p.0-0, 2022

1 January 2024 in Brazilian Journal of Biology
Verified
Journal Article
Open access
PDF file
CIC. T. M. I. Issa
C. T. M. I. Issa
RCRicardo Castro
Ricardo Castro
KAK. L. G. D. Albuquerque
K. L. G. D. Albuquerque
Parkinson’s disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in the production of dopamine. Medication with levodopa becomes less effective as the disease progresses. Despite the excellent results observed in clinical practice with the medicinal use of Cannabis in the treatment of PD, the level of scientific evidence is still limited due to the small number of studies published in this field. We present the case of a 77-year-old man diagnosed 22 years ago with PD in an advanced stage, with significant bradykinesia, tremor, and rigidity along with the inability to maintain an upright position and walk, exacerbated by a femur fracture. He also had advanced dysphagia, resulting in a gastrostomy. Although lucid, he showed no interest in conversation and tended to become depressed and isolated. He used Prolopa® with no satisfactory therapeutic response. After starting treatment with Cannabis sativa oil, he is now able to walk around the house frequently and eat pasty food regularly without choking or broncho-aspiration episodes. There has also been a significant improvement in non-motor symptoms; he is more active, cheerful, communicative, and attentive to his surroundings. Further studies are needed to elucidate these results and the mechanisms of action of cannabinoids through which they exert possible neuroprotective and neuroreparative effects. These compelling results suggest that cannabis oil may offer a valuable and effective therapeutic option for individuals with Parkinson's disease.

1 January 2025 in Brazilian Journal of Biology
Verified
Journal Article
Open access
LPL. V. Pinheiro
L. V. Pinheiro
EPE. L. L. Prado
E. L. L. Prado
MJM. S. Januzzi
M. S. Januzzi
CIC. T. M. I. Issa
C. T. M. I. Issa
KAK. L. G. D. Albuquerque
K. L. G. D. Albuquerque
KTK. H. L. Turcio
K. H. L. Turcio
Medicinal cannabis has been the subject of extensive research, with recent studies demonstrating its potential in managing chronic pain and enhancing quality of life. This case report examines the use of medicinal cannabis in a patient treated at the School of Dentistry of Araçatuba (FOA-UNESP). The patient, a 28-year-old female with no comorbidities, presented with chronic muscular TMD and reported poor sleep quality. Full-spectrum cannabis oil (1:1 ratio of THC to CBD), was prescribed for a period of 60 days, with a maximum dosage of 10 drops per day. Pain intensity was measured using the Visual Analog Scale (VAS), while sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Evaluations were conducted at three intervals: baseline, day 30, and day 60. To ensure patient safety, pre- and post-treatment blood tests were performed, and dosage adjustments were made every three days under the supervision of the study’s medical team. The results revealed significant improvements in pain management, with the patient’s orofacial pain score decreasing from 7 to 3 on the NRS. Additionally, sleep quality improved, as reflected by a lower PSQI score (global sleep quality at level 6 at the end), indicating more restorative sleep. Throughout the treatment period, the patient experienced mild side effects, including drowsiness and gastrointestinal discomfort, which were effectively managed through dosage modifications. In conclusion, full-spectrum cannabis oil shows promise as a therapeutic strategy for managing orofacial pain and improving sleep quality, providing significant relief in conditions where other interventions are ineffective or poorly tolerated. Further research is warranted to better understand the therapeutic mechanisms and potential side effects of medicinal cannabis in the management of chronic pain and related conditions.

26 August 2026 in Autism Research
Verified
Journal Article
Open access
PDF file
WMWandersonia Moreira Brito Medeiros
Wandersonia Moreira Brito Medeiros
EJEstácio Amaro da Silva Junior
Estácio Amaro da Silva Junior
KAKaty Lísias Gondim Dias de Albuquerque
Katy Lísias Gondim Dias de Albuquerque
MRMarine Diniz da Rosa
Marine Diniz da Rosa
AOAmanda Gleiciane de Lima Oliveira
Amanda Gleiciane de Lima Oliveira
NTNelson Torro‐Alves
Nelson Torro‐Alves
To evaluate, in a post hoc subanalysis, the effects of cannabidiol (CBD)‐rich cannabis oil on facial expression recognition and theory of mind in children with autism spectrum disorder (ASD). This post hoc subanalysis included children from a double‐blind, randomized, placebo‐controlled trial who completed social cognition assessments at baseline and after treatment. Participants received CBD‐rich cannabis oil or placebo for 12 weeks. Facial expression recognition and theory of mind were assessed using neuropsychological tasks. Between‐group differences were evaluated using the Mann–Whitney U test, whereas within‐group changes were assessed using the Wilcoxon signed‐rank test. Nineteen Brazilian children with ASD were included (72.7% male; mean age, 7.82 years). Within‐group analyses showed significant improvements in facial expression recognition ( p = 0.030) and verbal theory of mind ( p = 0.016) after treatment in the CBD group, whereas corresponding changes in the placebo group were not statistically significant. However, between‐group comparisons showed no significant differences after treatment in facial expression recognition ( p = 0.527) or verbal theory of mind ( p = 0.901). Total theory of mind scores improved significantly within both groups, with no significant between‐group difference ( p = 0.967). Although significant within‐group improvements in facial expression recognition and verbal theory of mind were observed following CBD‐rich cannabis oil treatment, these changes were not significantly different from those observed with placebo. Given the small sample size and exploratory post hoc design, these findings should be interpreted cautiously and do not establish a treatment effect of CBD on social cognition in children with ASD. Trial Registration: Brazilian Clinical Trials Registry (ReBEC), RBR‐5wr2cqq (UTN: U1111‐1261‐4178), accessible at https://ensaiosclinicos.gov.br/rg/RBR‐5wr2cqq

22 March 2025 in Revista Brasileira de Medicina de Família e Comunidade
Verified
Journal Article
Open access
PDF file
APAna Beatriz Medeiros e Paula
Ana Beatriz Medeiros e Paula
IAIgor Bronzeado Cahino Moura de Almeida
Igor Bronzeado Cahino Moura de Almeida
LLLuíza Alcântara Pontes de Lemos
Luíza Alcântara Pontes de Lemos
KAKaty Lísias Gondim Dias de Albuquerque
Katy Lísias Gondim Dias de Albuquerque
Introdução: O Transtorno do Espectro Autista (TEA) caracteriza-se por déficits na comunicação e na interação social, além de comportamentos repetitivos e restritivos, geralmente manifestados por volta dos 3 anos. Objetivos: Avaliar a resposta terapêutica de cinco pacientes pediátricos com TEA que utilizaram óleo de cannabis full spectrum rico em canabidiol (CBD) 20 mg/ml associado ao tratamento medicamentoso convencional, acompanhados na Atenção Primária à Saúde no primeiro semestre de 2024. Métodos: Realizou-se um estudo observacional e descritivo, do tipo série de casos, baseado em busca ativa em prontuários digitais. Utilizaram-se instrumentos validados para diagnóstico e avaliação clínica (Childhood Autism Rating Scale - CARS e Autism Treatment Evaluation Checklist - ATEC), além de roteiro semiestruturado fundamentado na Case Report (CARE checklist), permitindo a coleta de dados essenciais sobre a evolução dos pacientes que faziam uso complementar do óleo de cannabis. Resultados: Dos cinco pacientes, três eram meninos e duas meninas, entre 5 e 11 anos. Dois foram classificados com autismo grave e três com autismo leve a moderado. A média de idade ao diagnóstico foi de 42,6 meses, e o uso de CBD durou, em média, 7,4 meses. Todos apresentaram melhora expressiva em sintomas como agressividade, insônia, hiperatividade, interação social, comportamentos repetitivos, seletividade alimentar e concentração. As medicações associadas incluíram risperidona, clorpromazina, lamotrigina e topiramato, sendo a risperidona a mais utilizada. Conclusão: O óleo de cannabis rico em CBD demonstrou efeitos terapêuticos positivos em pacientes com sintomas persistentes do TEA, sem registro de eventos adversos relacionados ao seu uso inicial.